银杏叶提取物制剂、阿司匹林及氯吡格雷抗血小板聚集作用比较及对血小板活化因子含量的影响

中国临床药理学与治疗学 ›› 2011, Vol. 16 ›› Issue (9): 998-1001.

银杏叶提取物制剂、阿司匹林及氯吡格雷抗血小板聚集作用比较及对血小板活化因子含量的影响

王如伟¹, 吕燊¹, 黄黎¹, 徐露², 董志²

¹浙江中药与天然药物研究院,浙江省中药利药技术重点实验室,杭州 310052,浙江;
²重庆医科大学药学院重庆市生化与分子药理重点实验室,重庆 400016

收稿日期:2011-07-07 修回日期:2011-08-25 出版日期:2011-09-26 发布日期:2011-10-11
作者简介:王如伟,男,博士生导师,研究方向:中药药理。Tel: 13588431182 E-mail: lus@conbagroup.com
基金资助:
浙江省重点实验室和中试基地计划项目(2009E10009);浙江省重大科技专项重点社会发展项目(2009C13027)

Comparasion of anti-platelet aggregation and PAF decrease effect among EGB,Asprin and Plavix

WANG Ru-wei¹, LV Shen¹, HUANG Li¹, XU Lu², DONG Zhi²

¹Zhejiang Chinese Medicine and Natural Drug Research Institute, Zhejiang Provinical Key Laboratory of Traditional Chinese Medicine Pharmacecutical Techonology, Hangzhou 310052, Zhejiang, China;
²Chongqing Medical University, Chongqing 400016, China

Received:2011-07-07 Revised:2011-08-25 Online:2011-09-26 Published:2011-10-11

摘要/Abstract

摘要： 目的: 观察银杏叶提取物(EGB)制剂、阿司匹林及氯吡格雷对家兔血小板聚集率及血小板活化因子(PAF)含量的影响。方法: 采用体内实验,观察EGB制剂、阿司匹林及氯吡格雷对由花生四烯酸(AA)、二磷酸腺苷(ADP)和PAF诱导的家兔血小板聚集作用的影响,以及对给药前后家兔PAF含量的影响。结果: 与生理盐水组比较,EGB制剂抑制AA、ADP、PAF诱导的家兔血小板聚集有统计学差异(P<0.05,P<0.01),并能够降低血清中PAF的含量(P<0.05),阿司匹林对AA诱导的血小板聚集有统计学差异(P<0.01),氯吡格雷对ADP诱导的血小板聚集有统计学差异(P<0.01),而阿司匹林和氯吡格雷对PAF的含量没有显著影响。结论: EGB制剂具有抗血小板聚集作用,抗PAF诱导的血小板聚集作用最强,并能显著降低PAF含量。

关键词: 银杏叶提取物制剂, 抗血小板聚集, 血小板活化因子

Abstract: AIM: To compare the effect of anti-platelet aggregation function and the PAF's contect among the EGB preparation,Asprin and Plavix. METHODS: Experiment in vivo was used to observe the platelet aggregation effect induced by AA,ADP,PAF among the EGB preparation,Asprin,Plavix. RESULTS: Compared with saline group,EGB could significantly inhibit the platelet aggregation induced by AA,ADP,PAF (P<0.05, P<0.01), reduce the PAF's content in serum(P<0.05); Asprin could significantly inhibit the platelet aggregation induced by AA (P<0.01); Plavix could significantly inhibit the platelet aggregation induced by ADP (P<0.01); Asprin and Plovix had no significantly different on PAF's content(P>0.05). CONCLUSION: EGB has anti-platelet aggregation function, and can reduce the PAF's content in serum.

Key words: EGB preparation, Anti-platelet aggregation, Platelet activating factor

中图分类号:

R965.2

王如伟, 吕燊, 黄黎, 徐露, 董志. 银杏叶提取物制剂、阿司匹林及氯吡格雷抗血小板聚集作用比较及对血小板活化因子含量的影响[J]. 中国临床药理学与治疗学, 2011, 16(9): 998-1001.

WANG Ru-wei, LV Shen, HUANG Li, XU Lu, DONG Zhi. Comparasion of anti-platelet aggregation and PAF decrease effect among EGB,Asprin and Plavix[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2011, 16(9): 998-1001.

[1]	徐露, 董志. 注射用羟基红花黄色素A对家兔血小板聚集、超微结构及血小板活化因子诱导后富血小板血浆中GMP-140含量的影响[J]. 中国临床药理学与治疗学, 2012, 17(3): 269-273.
[2]	李娟, 陈红专. 血小板活化因子在中枢神经系统中的双重活性及在新药开发中的价值[J]. 中国临床药理学与治疗学, 2007, 12(3): 270-274.
[3]	彭昕, 董志. 脑缺血再灌注损伤的炎症反应机理研究进展[J]. 中国临床药理学与治疗学, 2006, 11(4): 366-368.